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Abstract 
Objective:To detect and quantify peripheral nerve lesions in multiple sclerosis (MS) by 
magnetic resonance neurography (MRN). 
Methods: 36 patients diagnosed with MS based on the 2010 McDonald criteria (34 with the 
relapsing-remitting form, 2 with clinically isolated syndrome) with and without disease 
modifying treatment were compared to 35 healthy age/sex-matched volunteers. All patients 
underwent detailed neurological and electrophysiological examinations. 3T MRN with large 
anatomical coverage of both legs and the lumbosacral plexus was performed by using 2D fat-
saturated, T2-weighted and dual echo turbo-spin-echo sequences as well as a 3D T2-
weighted, fat-saturated SPACE sequence. Besides qualitative visual nerve assessment, a T2w-
signal quantification was performed by calculation of proton-spin-density and T2-relaxation 
time. Nerve diameter was measured as a morphometric criterion.  
Results:T2w-hyperintense nerve lesions were detectable in all MS patients with a mean 
lesion number at thigh level of 151.5±5.7 vs. 19.1±2.4 in controls (p<0.0001). Nerve proton-
spin-density was higher in MS (tibial/peroneal: 371.8±7.7/368.9±8.2) vs. controls 
(tibial/peroneal: 266.0±11.0/276.8±9.7;p<0.0001). In contrast, T2-relaxation time was 
significantly higher in controls (tibial/peroneal:82.0±2.1/78.3±1.7) vs. MS 
(tibial/peroneal:64.3±1.0/61.2±0.9; p<0.0001). Proximal tibial and peroneal nerve caliber was 
higher in MS (tibial:52.4±2.1mm²; peroneal:25.4±1.3mm²) vs. controls (tibial:45.2±1.4mm²; 
p<0.0015; peroneal:21.3±0.7mm²; p=0.0049).  
Interpretation:Peripheral nerve lesions could be visualized and quantified in MS in vivo by 
high resolution MRN. Lesions are defined by an increase of proton-spin-density and a 
decrease of T2-relaxation time, indicating changes in the microstructural organization of the 
extracellular matrix in peripheral nerve tissue in MS. By showing involvement of the 
peripheral nervous system in MS, this proof-of-concept study may offer new insights into the 
pathophysiology and treatment of MS.  
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Introduction 
Multiple sclerosis (MS), one of the most common acquired chronic neurological diseases, is 
traditionally regarded as restricted to the CNS, but the exact etiology is still unclear. With an 
estimated prevalence of 2 million affected people worldwide, it is one of the leading causes of 
disability in young adults.
1
 The clinical presentation of MS is heterogeneous with sensory, 
motor, visual and autonomic symptoms.  
Clinically, MS is diagnosed based on the principles of symptom dissemination in space and 
time as defined by the Poser criteria.
2
 According to the 2010 McDonald criteria, the early 
diagnosis of MS after a single clinical event can be established by the radiological 
demonstration of lesion dissemination in space and time.
3
   
Few studies, most of them case reports, suggest the concurrence of demyelination in the 
central nervous system (CNS) and peripheral nervous system (PNS) in MS. Earlier 
neuropathological reports described segmental demyelination, hypertrophic neuropathy and 
reduction in myelin thickness in few MS patients.
4,5
 Large electrophysiological studies of 
nerve conduction abnormalities in MS are rare and documented results are inhomogeneous 
regarding type, frequency and extent of PNS involvement.
6,7
  
High-resolution magnetic resonance neurography (MRN) enables early detection and precise 
localization of peripheral nerve lesions with high sensitivity, down to the level of nerve 
fascicles in various neuropathies, and thus can overcome typical diagnostic limitations of 
nerve conduction studies (NCS).
8,9
 With an extensive MRN imaging protocol and in 
correlation with NCS, we 1) tested the involvement of the PNS in MS, 2) analyzed peripheral 
nerve lesions by in vivo visualization, localization and T2w-signal quantification, and 3) 
compared MRN findings of healthy volunteers to those of MS patients in correlation with the 
presence of spinal cord lesions. 
 
Materials and methods 
Study design and patients  
The local ethics committee approved this study (University of Heidelberg S-405/2012; J.P., 
M.B.) and all participants gave written informed consent. 36 MS patients (21 female, 15 male, 
mean age 32.1 years, range 18-43, 2010 McDonald criteria fulfilled in all patients) with either 
relapsing-remitting MS (>3 years, range 3-13; n=34) or with clinically isolated syndrome 
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(n=2) and 35 sex and age matched healthy volunteers (19 female, 16 male, mean age 31.6, 
range 22-40), were included in this prospective, cross-sectional, single center study between 
May 2015 and September 2016. Current Gadolinium-enhanced MRI studies of the brain and 
spine were available in all patients with MS. The mean time gap between the acquisition of 
the MRN scans and the most recent available CNS MRI was 1.5±0.3 months (median = 1 
month) for imaging of the brain and 5.5±1.3 months (median = 3 months) for imaging of the 
spinal cord. Overall exclusion criteria were, age <18 or >45, pregnancy, any contraindications 
for MRI, any risk factors for neuropathy such as diabetes mellitus, alcoholism, malignant or 
infectious diseases, any therapy with steroids in the eight weeks immediately prior to the MRI 
scans, and any previous exposure to neurotoxic agents. Additionally, by taking a detailed past 
medical history, any sensory or motor symptoms in the upper or lower extremities, any 
history of neuropathy, any previous spine surgery, and any permanent medication was ruled 
out in all healthy volunteers.  
 
Clinical and electrophysiological examination 
A detailed medical history was documented for each patient and a comprehensive 
neurological examination (R.D.; B.W.; M.K.K.) was performed, including evaluation of the 
Expanded Disability Status Scale.
10
 NCS of the left leg included: distal motor latencies, 
compound muscle action potentials, and F-waves of the tibial and peroneal nerves, nerve 
conduction velocities of the tibial, peroneal and sural nerves, and sensory nerve action 
potentials of the sural nerve (M.W.). Skin temperature was controlled at a minimum of 32°C. 
Detailed clinical and electrophysiological data are presented in Table 1 and 2. 
 
MRN protocol 
All participants underwent high-resolution MRN in a 3.0 Tesla MR-scanner (Magnetom TIM-
TRIO, Siemens Healthcare, Erlangen, Germany):  
(1) 3D T2-weighted inversion recovery SPACE (Sampling Perfection with Application-
optimized Contrasts using different flip angle Evolution) sequence for imaging of the 
lumbar plexus and spinal nerves with 50 axial reformations/patient: repetition time / 
effective echo time / inversion time 3000 / 62 / 210 ms, field of view 305 x 305 mm
2
, 
Page 4 of 29
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
5 
 
matrix size 320 x 320 x 104, slice thickness 1.0 mm, no gap, voxel size 1.0 x 1.0 x 1.0 
mm
3
, acquisition time 8:32 min. 
(2) Axial high resolution T2-weighted turbo spin echo 2D-sequences with spectral fat-
saturation (three slabs at the right leg). Slab 1: proximal thigh to mid-thigh; slab 2: 
lower leg with alignment of its proximal edge with the tibiofemoral joint space; slab 3: 
ankle level with alignment of the distal edge of the imaging slab on the tibiotalar joint 
space. Repetition time / echo time 5970 / 55 ms, field of view 150 x 150 mm
2
, matrix 
size 512 x 512, slice thickness 3.5 mm, interslice gap 0.35 mm, voxel size 0.4 x 0.3 x 
3.5 mm
3
, 35 slices, acquisition time per slab 4:42 min. 
(3) Axial high-resolution dual echo turbo spin echo 2D-sequence with spectral fat 
saturation (one slab per leg, equaling two slabs per subject): mid-thigh to distal thigh 
with alignment of the distal edge of this imaging-slab on the tibiofemoral joint space. 
Repetition time 5210 ms, echo time1 / echo time2 12 / 73 ms, field of view 150 x 150 
mm
2
, matrix size 512 x 512, slice thickness 3.5 mm, interslice gap 0.35 mm, voxel 
size 0.4 x 0.3 x 3.5 mm
3
, 35 slices, acquisition time per slab 7:30 min.  
 
Net imaging time including survey scans was 38:02 min. Patient and coil repositioning 
required additional time, resulting in a total examination time of 60-70 min per participant. A 
4-channel body-array flex-coil (Siemens Healthcare) was used for imaging of the lumbar 
plexus (sequence 1), and a 15-channel Transmit-Receive extremity-coil (INVIVO) for 
imaging of the right and left leg, respectively (sequence (2) and (3)). All coils used in this 
study are commercially available. 
 
Image post-processing and statistical analysis  
All images generated by MRI sequences (2) and (3) were pseudonymized (M.B.; J.P.) and 
subsequently analyzed in FSL, a dedicated software for neuroimaging data evaluation.
11
 
Tibial and peroneal fascicles of the sciatic nerve and their distal continuation as either tibial or 
peroneal nerve were manually segmented by one neuroradiologist (G.H.H.) from proximal 
thigh down to distal ankle level on 140 axial slices for the left leg, and only at thigh level on 
additional 35 slices for the right leg. The contour between nerve fascicles and the epineurium 
was used as a reliably visible segmentation border. Slice numbering for the tibial nerve was 
from 0 (most proximal slice at proximal thigh level) to 139 (most distal slice at ankle level) 
and from 0 to 60 (level of the fibular head) for the peroneal nerve. For simplification, we refer 
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to tibial fascicles of the sciatic nerve and corresponding tibial nerve as tibial nerve only, and 
to peroneal fascicles of the sciatic nerve and corresponding common peroneal nerve as 
peroneal nerve.  
 
Qualitative evaluation of nerve lesions 
Based on the 2010 McDonald criteria, the evaluation of T2w hyperintense lesions in the brain 
and spinal cord is an established method in the initial diagnostic work-up of patients with MS, 
as well as in their lifelong radiological follow up. According to this standard procedure, two 
experienced, independent neuroradiologists (J.J; J.K.) who were blinded to clinical data, 
performed a visual evaluation and determination of the total sciatic nerve lesion count on 20 
representative axial imaging slices at left proximal thigh level. We defined a nerve lesion as a 
nerve fascicle with an abnormally high T2w signal. Lesion number per slice position was 
counted and then summed to a total lesion number within the imaged volume per participant. 
Subsequently, mean values were calculated over all participants within either the MS or the 
control group.   
Recent spinal cord MRIs of all MS patients were additionally analyzed to exclude potential 
external sources of nerve affection such as spinal cord or nerve root compression due to 
herniated vertebral disks or spinal tumors. Once external reasons for nerve damage were ruled 
out, the total number of T2w hyperintense lesions to the spinal cord was evaluated. The total 
number of spinal cord lesions was then correlated with the total number of sciatic nerve 
lesions at thigh level. 
 
Tibial and peroneal nerve T2w signal 
In previous studies on nerve lesion detection and quantification in two different 
polyneuropathies,
12,13
 we performed an extensive histogram based normalization of nerve 
T2w signal intensities and an fully-automatic and operator-independent binary classification 
of respective tibial and peroneal nerve voxels as either nerve lesion voxels or non-lesion 
voxels. With this method we have already proven, that an increase of nerve T2w signal 
reflects true nerve lesions.
12,13
 To facilitate statistical evaluations, we analyzed nerve T2w 
signal without any further signal normalization in the current study. 
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Mean nerve T2w signal was calculated per slice position for each subject and for each left leg. 
To receive detailed information about the anatomical distribution of nerve lesions and thereby 
information about the location of predominant nerve affection, we compared mean tibial 
nerve T2w signals of 35 slices at proximal to mid-thigh level (slice positions 0-35) to its distal 
equivalent of 35 slices at the lower leg (proximal to middle part; slice positions 70-105). The 
peroneal nerve was evaluated from proximal to mid-thigh level (slice positions 0-35) only. 
Averaged mean values within all proximal slices were statistically compared between the two 
groups (MS versus controls) by using the Mann-Whitney test; additional mean values within 
all distal slices were evaluated for the tibial nerve only.   
 
Nerve lesion quantification: apparent T2 relaxation time and proton-spin-density 
Quantification of nerve lesions was performed by calculating the apparent T2 relaxation time 
(T2app, Equation 1) and  proton spin density (ρ, Equation 2), by the following formulas:
14
 
 
 
 
 
 
 
As indicated by the two formulas, calculation of T2app and ρ required the acquisition of an 
additional pulse sequence at two different echo times (sequence (3) with echo time1 = 12 ms 
and echo time2 = 73 ms). To hold a reasonable total acquisition time, the dual echo sequence 
was acquired at thigh level only. That was done in accordance with previous studies in 
different neuropathies, where we have already proven their feasibility of application in the 
PNS, and their high sensitivity for early nerve lesion detection.
12 13
 
 
Morphometric quantification: Nerve diameter 
Nerve caliber was analyzed by measuring the complete cross sectional area of the tibial and 
peroneal nerve on each axial slice. Two-way ANOVA was performed to test group 
differences (MS versus controls) and differences between anatomical regions (proximal slice 
1) 
 
2) 
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positions 0-69 versus distal slice positions 70-139). Peroneal nerve caliber was analyzed from 
proximal thigh level down to the level of the fibular head only (slice positions 0-60). 
 
Lumbosacral plexus and spinal nerves 
Bilateral dorsal root ganglia and corresponding proximal spinal nerves L5 and S1 were 
segmented on axial reformations of sequence (1) by manually delineating the nerve 
circumference as the intraneural region of interest. In the same manner, the lumbosacral 
plexus was segmented at level of the sciatic notch on both sides. Subsequently, signal ratios 
between intraneural regions of interest and ipsilateral psoas (L5 and S1) or piriformis muscle 
(plexus) were calculated. Additional quantification of spinal nerve and plexus caliber was 
performed by measuring the cross sectional area of the corresponding nerve on each axial 
slice. 
 
Statistical analysis 
Statistical data analysis was performed with GraphPad Prism 6 (J.K; J.M.H.). Differences 
between MS patients and controls were evaluated with the Mann-Whitney test. Where 
appropriate, a one-way or two-way ANOVA was used for a priori assumptions, and 
subsequent post hoc comparisons were evaluated with the Fisher test. Statistical tests were 
two-tailed and an alpha-level of significance was defined at p < 0.05. All results are 
documented as mean values ± Standard Error of the Mean (SEM). 
 
Results 
Clinical and electrophysiological data 
There was no significant difference between MS patients and controls for age, sex, body 
weight and height (Table 1). In MS patients, the mean overall EDSS score was 2.0 ± 0.3. 31 
patients received disease-modifying medical treatment (EDSS 2.0 ± 0.3), while five patients 
had been free of immunomodulating medical treatment during the course of their disease 
(EDSS 2.1 ± 0.9). All patients fulfilled the revised 2010 McDonald criteria (Supplementary 
Table 1). Electrophysiological findings were normal with the exception of four patients 
having marginally amplitude-reduced sural sensory nerve action potentials (ID 11, 13, 15; 
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Supplementary Table 2), one patient having non-elicitable F-waves of the peroneal nerve (ID 
23; Supplementary Table 2), and another one with non-elicitable F-waves of the tibial and 
peroneal nerves (ID 15; Supplementary Table 2) in otherwise normal electroneurographic 
parameters and without clinical evidence of peripheral nerve dysfunction (Supplementary 
Table 2).  Moreover, there was no evidence for metabolic or vasculitic neuropathy in CSF- or 
blood tests (e.g. metabolic panel, vitamin B12) at the time of diagnosis. Lumbar MRI ruled 
out concurrent nerve root compression.  
 
Qualitative evaluation of nerve lesions  
Qualitative visual evaluation revealed marked T2w-hyperintense nerve lesions in all MS 
patients independent of their prior medication and with a mean lesion number at thigh level of 
152.7 ± 4.1 versus 19.3 ± 1.7 in controls (p < 0.0001). Further subgroup analyses between 
treated MS patients versus controls and also between untreated MS patients versus controls 
revealed high differences for both groups (p < 0.0001; Fig 1 and 2), while differences 
between treated and untreated MS patients were not significant (p = 0.64). Calculated Cohens 
kappa was 1.000 for inter-observer reliability to visually classify all participants into either 
MS or non-MS. High inter-observer reliability was also found for the subsequent evaluation 
of the sciatic nerve lesion count (lesion number) with a Pearson´s r of 0.9978 (control group) 
and 0.9892 (MS group). Fascicular lesions in all MS patients showed a diffuse distribution 
pattern with a median length of 7.35 mm, not involving fascicular segments longer than 11.2 
mm.  
The additional evaluation of spinal cord T2w lesions in MS patients revealed a strong 
negative correlation between spinal cord lesions and sciatic nerve lesions (r=-0.51; p=0.002). 
In all MS patients we found no spinal cord T2w lesions below lumbar segment 1 (L1) and no 
signs of spinal cord or nerve root compression. 
 
Proton spin density 
The Mann-Whitney test revealed higher ρ in MS patients (tibial nerve: 371.8 ± 7.7; peroneal 
nerve: 368.9 ± 8.2 a.u.) versus healthy controls (tibial nerve: 266.0 ± 11.0; peroneal nerve: 
276.8 ± 9.7 a.u.; p < 0.0001 for both nerves).  
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As ρ was found to be the parameter with highest sensitivity for detecting PNS affection in MS 
patients, and to rule out that an increase of ρ was not related to the appearance of spinal cord 
lesions, we evaluated ρ in subgroups of MS patients with and without spinal cord lesions. 
One-way ANOVA revealed marked differences between the three groups (MS patients with 
spinal cord lesions versus MS patients without spinal cord lesions versus controls) with p < 
0.0001. Post-hoc comparisons showed significant differences of mean tibial nerve ρ between 
controls (26.0 ± 11.0 a.u.) versus MS with spinal cord lesions (368.0 ± 8.0 a.u.; p < 0.0001) 
and versus MS without spinal cord lesions (387.3 ± 21.9 a.u.; p < 0.0001; Fig 4), while 
differences between MS patients with and without spinal cord lesions were not significant (p 
= 0.45).  
 
Apparent T2 relaxation time 
Differences of T2app between MS patients and controls was highly significant (p < 0.0001 for 
both nerves), with higher T2app in controls (tibial nerve: 82.0 ± 2.1 ms; peroneal nerve: 78.3 
± 1.7 ms) compared to MS patients (tibial nerve: 64.3 ± 1.0 ms; peroneal nerve: 61.2 ± 0.9 
ms). 
Mean ρ and T2app are plotted for each group and nerve in Fig. 3. 
 
Nerve T2w-signal 
Proximal tibial and peroneal nerve T2w signal was not significantly different between MS 
patients (tibial nerve: 218.5 ± 6.3; peroneal nerve: 157.6 ± 4.6 a.u.) and controls (tibial nerve: 
210.6 ± 7.5; p = 0.40; peroneal nerve: 148.3 ± 4.6 a.u.; p = 0.12). T2w signal of the distal 
tibial nerve was also not significantly different between MS patients (148.3 ± 5.1) and 
controls (153.8 ± 6.5 a.u.; p = 0.55). A significantly higher tibial nerve T2w signal could be 
observed at thigh level versus lower leg level in MS as well as in controls (p < 0.0001).  
 
Morphometric quantification: Nerve diameter 
Differences in proximal nerve caliber (measured as mean cross-sectional area) between MS 
patients and controls were significant at the level of the lumbosacral plexus and spinal nerves, 
(MS group: lumbosacral plexus 90.6 ± 4.8, spinal nerve L5 47.6 ± 1.9, spinal nerve S1 / 47.8 
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± 2.0 mm²; control group: lumbosacral plexus 34.3 ± 1.5, spinal nerve L5 16.4 ± 0.6, spinal 
nerve S1 13.2 ± 0.6 mm²; p < 0.0001 for all locations). Differences in proximal nerve caliber 
were also significant for the tibial nerve (MS group 52.4 ± 2.1 mm²; controls 45.2 ± 1.4 mm²; 
p = 0.0015) and the peroneal nerve (MS group 25.4 ± 1.3 mm²; controls 21.3 ± 0.7 mm²; p = 
0.0049). However, distally, at lower leg level, there was no significant difference of tibial 
nerve ca iber between MS patients (34.2 ± 1.8 mm²) and controls (32.1 ± 0.9 mm²; p = 0.35).  
 
Discussion 
To date, it is widely accepted that pathological changes in MS are restricted to the CNS and 
cranial nerves. This is reflected by the revised 2010 McDonald criteria which only consider 
cerebral or spinal cord inflammatory lesions. Moreover, electrophysiological tests are 
commonly negative for signs of PNS involvement in MS. However, in many patients 
suffering from MS, there is a large, yet inexplicable gap, between the severity of clinical 
symptoms and a comparably low burden of CNS lesions.
15,16
 Few studies have indicated that 
damage might occur in parts of the PNS as well,
17,5,18,7
 but to date, there is no solid proof of a 
distinct PNS affection in vivo.  
 
To the best of our knowledge, our study is the first to prove an involvement of the PNS in MS 
patients by high-resolution MRN regardless of disease duration or medical treatment. Similar 
to the established diagnostic evaluation of T2w-hyperintense lesions in the brain and spinal 
cord, lesion number of the PNS can be determined visually by counting single T2w-
hyperint nse fascicles within lower extremity peripheral nerves with high inter-rater 
reliability (Fig. 1 and 2). Further signal quantification revealed a highly significant increase of 
ρ in MS patients compared to healthy controls, while T2app was significantly lower in the MS 
cohort (Fig. 3). Both, ρ and T2app contribute to the T2w signal. However, as defined by the T2 
decay, which can be calculated according to the formula S(TE)=ρ*exp(-TE/T2app) (S=signal, 
TE=echo time), an overall T2w signal increase is possible when there is an increase in ρ or 
T2app, or the increase of one of the two parameters outweighs the decrease of the other. In 
our study cohort, the observed visual increase of fascicular T2w signal was mainly generated 
by an increase of ρ, which according to the T2 decay formula, outweighed the decrease of 
T2app with regards to the signal in the T2 weighted sequence.  
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The subsequent classification of PNS lesions as areas of elevated ρ and slightly reduced T2app 
suggests, that an increase in free-water protons, as one would expect in endoneural edema, is 
not the main underlying pathomechanism of PNS involvement in MS.
19,20
 Instead, an 
increasing ρ indicates that damage to the PNS in MS is more likely induced by changes in the 
microstructural organization of the extracellular matrix as a consequence of an increase in 
plasma protein leakage through the endovascular barrier, and the pathogenesis of a pro-
inflammatory milieu.
21
 This mechanism was previously hypothesized as key factor in the 
pathomechanism of typical PNS diseases like amyloidotic or diabetic neuropathy.
12,13
 
Additionally, previous MRI studies focusing on changes of ρ in CNS lesions related to MS, 
found a clear correlation between an increased ρ and areas of demyelination in the brain and 
spinal cord,
22
 suggesting that our findings represent a peripheral co-demyelination of the PNS 
in MS. Thus, an increase in ρ supports the assumption that PNS lesions or rather a peripheral 
co-demyelination is likely to be caused by immunologic reactions and destruction of 
molecules such as connexin 32 or myelin associated glycoproteins that are common to 
myelinating cells in both, the PNS and the CNS.
23,24,25
.  
 
Alterations of T2app in MS are still not fully understood.
26
 Previous studies described an initial 
increase of T2app in acute MS lesions with a subsequent decrease in chronic lesions, but 
results are controversial.
27,28,29,30
 One possible explanation might be a balance change of the 
total water pool, towards a higher amount of bound water and a lower amount of free water 
molecules, as it would be the case in the suggested hypotheses of an inflammatory process 
combined with an impairment of the blood nerve barrier, a pathologically high plasma protein 
leakage and an impairment of the lipid-rich myelin sheath. 
1,21
 
 
Peripheral nerve lesion detection by means of the described qualitative and quantitative 
analysis of the MR signal was further validated by an additional increase of proximal tibial 
and peroneal nerve caliber in MS, representing a pure morphometric MRN criterion for nerve 
impairment. This proximal nerve caliber increase might also point towards an inflammatory 
process, especially as it was associated with a higher PNS lesions number and an increased ρ.   
However, differences between MS patients and healthy controls were insignificant for distal 
tibial nerve caliber, suggesting a proximal predominance of PNS affection  
 
This study is limited by the fact that most enrolled patients were under disease-modifying 
treatment.  An argument could be made that lesions are attributed to secondary effects of MS 
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modifying medications rather than to the disease itself. To the contrary, we found no 
difference in the lesion number of patients with and without medication. Furthermore, MS 
patients were treated with a multitude of different immunomodulating drugs, of which none 
have known acute or chronic neurotoxic side effects. One might also argue that, in 
comparison to controversial results in previous studies, but also in the absence of positive 
electrophysiological examination results, our finding of an elevated number of PNS lesions in 
all included patients seem improbable. An explanation might be that PNS involvement is very 
subtle in many cases and thus may escape detection by regular NCV exams, as in our study. 
However, recent studies focusing on demyelinating processes in corneal fibers of the 
trigeminal nerve have shown that PNS demyelination is present in more patients than clinical 
symptoms might suggest.
31
 Both, corneal fiber microscopy and MRN have already shown that 
damage to PNS fibers is detectable prior to the beginning of clinical symptoms.
12,31,32
  
 
A potential factor that might contribute to the occurrence of PNS lesions might be that PNS 
lesions are the result of Wallerian degeneration caused by spinal cord lesions in MS.
9
 
Although we cannot fully exclude such secondary effects of CNS lesions, we found no 
differences in MRN markers between patients with and without spinal cord lesions (Fig. 4). 
The finding of a negative correlation between PNS lesions and spinal cord lesions and also the 
exclusion of any other potential sources of CNS damage in the additionally available spinal 
MRIs, makes it even more unlikely that the observed PNS lesions occur as a direct 
consequence of spinal cord lesions. Furthermore, the diffuse, non-focal PNS lesion 
distribution in our study cohort that involved only short continuous fascicular segments, 
points more towards an underlying inflammatory or demyelinating pathomechanism as one 
would expect in MS. In contrast, an involvement of longer fascicular segments or a 
somatotopic fascicular organization as it has been demonstrated in Wallerian 
degeneration,
33,34,35,36
 could be excluded. Electrophysiological examinations also revealed no 
abnormalities due to an axonal loss, as they typically occur in Wallerian degeneration. For all 
these reasons, our study results indicate a potential occurrence of different antibodies in MS 
with and without CNS predominance.  
 
Future studies should point at differences in patients with MS and clinically isolated 
syndrome with and without PNS lesions. Special attention should be paid to individuals with 
a relatively low CNS lesion burden in comparison to severe clinical symptoms, and to the 
influence of different disease modifying drugs on the development of PNS lesions.  
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In summary, this proof-of-concept study evidences PNS lesions in young MS patients in vivo 
by MRN with high structural resolution. The identification of PNS lesions suggests a 
peripheral co-demyelination, which may guide to a better understanding of discrepancies 
between clinical symptoms and CNS lesions detected by MRI. Most importantly it provides 
options for new pathophysiological concepts, and the identification of potential distinct 
immunoreactions targeting PNS antigens in MS with future implications on therapeutic 
approaches.  
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Figure legend 
Figure 1: MRN source images. Representative MRN of the left sciatic nerve at mid-thigh 
level (high-resolution T2-weighted turbo spin echo sequence with spectral fat-saturation, 3T) 
in (A) a healthy control subject, (B) a patient with MS without disease modifying treatment 
and (C) a MS patient under disease modifying treatment. A high lesion number, measured as 
a marked T2w-hyperintensity in a multitude of sciatic nerve fascicles can be seen in MS 
patients without (B) and with (C) disease modifying treatment. Normal sciatic nerve T2w 
signal in a representative healthy control (A).    
 
Figure 2: Total sciatic nerve T2w lesion count. Mean values of the visually evaluated total 
nerve lesion number plotted for MS patients under immunomodulatory therapy (MS treated), 
MS patients without any current or previous immunomodulatory therapy (MS untreated), and 
controls. While differences between treated and untreated MS patients were not significant 
(p=0.64), differences between controls and each of the two MS subgroups were highly 
significant (p<0.0001).    
 
Figure 3: Quantitative MRN markers of nerve T2w signal. Mean values of tibial (left) and 
peroneal (right) proton spin density (A, B) and apparent T2 relaxation time (C, D) are plotted 
for MS patients and controls. Proton spin density of the tibial (A) and peroneal nerves (B) was 
significantly higher in MS patients versus healthy controls (p<0.0001). In contrast, tibial (C) 
and peroneal (D) apparent T2 relaxation time was significantly higher in controls versus MS 
patients (p<0.0001). 
 
Figure 4: Proton spin density. Mean values of tibial nerve proton spin density are plotted for 
MS patients with and without spinal cord T2w lesions and for controls. Note that differences 
in proton spin density between MS patients with and without T2w lesions to the spinal cord 
were not significant (p=0.45), while differences between controls and either MS subgroup 
were remarkable (p<0.0001). 
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Table 1: Demographic, clinical, radiological and electrophysiological data 
 
Parameter          MS patients          Controls            p value 
Age 32.1 ± 1.0 31.6 ± 1.3 0.25 (ns) 
Sex (M/F) 15/21 16/19 n.a. 
Body weight (kg) 73.6 ± 3.0 66.2 ± 1.5 0.10 (ns) 
Height (cm) 179.1 ± 3.6 175.9 ± 2.2  0.49 (ns) 
MS duration (months) 81.9 ± 7.3 n.a. n.a. 
Relapsing-remitting MS 34 n.a. n.a. 
Clinically isolated syndrome 2 n.a. n.a. 
Tibial nerve caliber (mm²) 52.4 ± 2.1 45.2 ± 1.4 0.0015 (**) 
Peroneal nerve caliber (mm²) 25.4 ± 1.3 21.3 ± 0.7 0.0049 (**) 
Total sciatic nerve T2w lesion number 152.7 ± 4.1 19.3 ± 1.7 <0.0001 (***) 
ρ tibial nerve 371.8 ± 7.7 266.0 ± 11.0 <0.0001 (***) 
ρ peroneal nerve 368.9 ± 8.2 276.8 ± 9.7 <0.0001 (***) 
Total CNS T2w lesions 27.9 ± 3.9 n.a. n.a. 
Cerebral T2w lesions 25.9 ± 3.7 n.a. n.a. 
Spinal T2w lesions 2.0 ± 0.4 n.a. n.a. 
CNS lesions with contrast enhancement 3 n.a. n.a. 
Tibial nerve CMAP [mV] 21.1 ± 1.4 n.a. n.a. 
Tibial nerve NCV [m/s] 54 ± 1 n.a. n.a. 
Tibial nerve F-wave [ms] 48.9 ± 0.6 n.a. n.a. 
Tibial nerve DML [ms] 3.6 ± 0.1 n.a. n.a. 
Peroneal nerve CMAP [mV] 7.7 ± 0.8 n.a. n.a. 
Peroneal nerve NCV [m/s] 50 ± 1 n.a. n.a. 
Peroneal nerve F-wave [ms] 46.2 ± 0.7 n.a. n.a. 
Peroneal nerve DML [ms] 3.7 ± 0.1 n.a. n.a. 
Sural nerve SNAP [µV] 14.0 ± 1.4 n.a. n.a. 
Sural nerve NCV [m/s] 57 ± 1 n.a. n.a. 
 
 
DML = distal motor latency; CMAP = compound muscle action potential; NCV = nerve conduction velocity; SNAP 
= sensory nerve action potential; ns = not significant, ** = significant, *** = highly significant 
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MRN source images. Representative MRN of the left sciatic nerve at mid-thigh level (high-resolution T2-
weighted turbo spin echo sequence with spectral fat-saturation, 3T) in (A) a healthy control subject, (B) a 
patient with MS without disease modifying treatment and (C) a MS patient under disease modifying 
treatment. A high lesion number, measured as a marked T2w-hyperintensity in a multitude of sciatic nerve 
fascicles can be seen in MS patients without (B) and with (C) disease modifying treatment. Normal sciatic 
nerve T2w signal in a representative healthy control (A).    
 
80x240mm (300 x 300 DPI)  
 
 
Page 21 of 29
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
  
 
 
Total sciatic nerve T2w lesion count. Mean values of the visually evaluated total nerve lesion number plotted 
for MS patients under immunomodulatory therapy (MS treated), MS patients without any current or previous 
immunomodulatory therapy (MS untreated), and controls. While differences between treated and untreated 
MS patients were not significant (p=0.64), differences between controls and each of the two MS subgroups 
were highly significant (p<0.0001).    
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Quantitative MRN markers of nerve T2w signal. Mean values of tibial (left) and peroneal (right) proton spin 
density (A, B) and apparent T2 relaxation time (C, D) are plotted for MS patients and controls. Proton spin 
density of the tibial (A) and peroneal nerves (B) was significantly higher in MS patients versus healthy 
controls (p<0.0001). In contrast, tibial (C) and peroneal (D) apparent T2 relaxation time was significantly 
higher in controls versus MS patients (p<0.0001).  
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Proton spin density. Mean values of tibial nerve proton spin density are plotted for MS patients with and 
without spinal cord T2w lesions and for controls. Note that differences in proton spin density between MS 
patients with and without T2w lesions to the spinal cord were not significant (p=0.45), while differences 
between controls and either MS subgroup were remarkable (p<0.0001).  
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Supplementary Table 1. Individual neurological deficits, EDSS scoring and current 
medications in MS patients 
 
ID Age/Sex EDSS 
Current neurologic 
examination findings 
Current medication 
1 33/F 4 Sensory: lower extremities Natalizumab 
2 36/F 2 Sensory: lower extremities Dimethyl fumarate 
3 30/M 0 Normal Interferon beta-1a 
4 39/F 1,5 Sensory: lower extremities Interferon beta-1a 
5 27/F 2 
Sensory: lower extremities 
Cranial nerves 
Fingolimod 
6 30/M 3 
Motoric: lower extremities 
Dimethyl fumarate 
Sensory: lower extremities 
7 34/F 3 
Motoric: lower extremities 
Interferon beta-1a 
Sensory: lower extremities 
8 38/F 3,5 
Sensory: lower extremities 
Autonomic nervous system 
No medication 
9 35/M 1,5 Normal Dimethyl fumarate 
10 39/M 3 
Sensory: upper and lower 
extremities 
No medication Motoric: upper and lower 
extremities 
Cranial nerves 
11 31/M 0 Normal Fingolimod 
12 22/F 3 
Sensory: upper and lower 
extremities 
Fingolimod 
13 36/M 0 Normal Dimethyl fumarate 
14 35/M 0 Normal Fingolimod 
15 39/M 4 
Motoric: upper and lower 
extremities 
Dimethyl fumarate 
Sensory: upper and lower 
extremities 
16 27/F 4 Motoric: lower extremities Natalizumab 
Page 25 of 29
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
Sensory: lower extremities 
17 21/F 1,5 Sensory: upper extremities Fingolimod 
18 34/F 0 Normal Fingolimod 
19 35/M 6,5 
Motoric: upper and lower 
extremities 
Natalizumab 
Sensory: upper and lower 
extremities 
Cranial nerves 
Autonomic nervous system 
20 40/M 2 Autonomic nervous system Natalizumab 
21 40/F 2 
Sensory: upper and lower 
extremities 
Natalizumab 
22 25/F 0 Normal Fingolimod 
23 18/F 3,5 
Motoric: upper and lower 
extremities 
Alemtuzumab      Sensory: upper and lower 
extremities 
Autonomic nervous system 
24 28/F 2,5 
Sensory: upper extremities 
Fingolimod 
Autonomic nervous system 
25 28/F 3,5 
Motoric: lower extremities 
Alemtuzumab 
Sensory: upper and lower 
extremities 
Autonomic nervous system 
26 25/F 2,5 
Motoric: upper and lower 
extremities 
Alemtuzumab Sensory: upper and lower 
extremities 
Cranial nerves 
27 39/M 2,5 Motoric: lower extremities Fingolimod 
28 35/M 0 
Motoric: lower extremities 
Dimethyl fumarate 
Autonomic nervous system 
29 27/F 1 Motoric: lower extremities Fingolimod 
30 31/F 3,5 
Motoric: upper and lower 
extremities 
Fingolimod Sensory: upper and lower 
extremities 
Cranial nerves 
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31 24/F 0 
Sensory: upper and lower 
extremities 
Dimethyl fumarate 
32 38/F 2 
Motoric: upper extremities 
Natalizumab Sensory: upper and lower 
extremities 
33 36/M 2 
Motoric: upper and lower 
extremities 
Alemtuzumab 
Sensory: lower extremities 
Cranial nerves 
34 28/F 0 Motoric: lower extremities No medication 
35 43/M 4 
Motoric: lower extremities 
No medication 
Autonomic nervous system 
36 31/M 0 Normal No medication 
 
Sensory = sensory dysfunction / symptoms; motoric = motoric dysfunction / symptoms 
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Supplementary Table 2. Individual electrophysiological study results in MS patients 
ID 
Tibial nerve 
motor conduction study 
 
Peroneal nerve  
motor conduction study 
 
Sural nerve 
sensory conduction 
study 
 
No. DML [ms] 
CMAP 
[mV] 
NCV [m/s] 
F-wave 
[ms] 
DML [ms] 
CMAP 
[mV] 
NCV [m/s] 
F-wave 
[ms] 
SNAP [µV] NCV [m/s] 
1 3.0 (N) 15.2 (N) 56 (N) 47.8 (N) 3.4 (N) 4.5 (N) 52 (N) 45.1 (N) 12.2 (N) 63 (N) 
2 4.1 (N) 21.6 (N) 59 (N) 45.7 (N) 3.6 (N) 8.6 (N) 52 (N) 42.1 (N) 19.4 (N) 52 (N) 
3 3.8 (N) 21.3 (N) 51 (N) 52.0 (N) 3.5 (N) 13.3 (N) 47 (N) 46,2 (N) 18.3 (N) 54 (N) 
4 3.2 (N) 24.0 (N) 55 (N) 45.9 (N) 3.0 (N) 7.6 (N) 52 (N) 42.2 (N) 14.9 (N) 55 (N) 
5 3.3 (N) 24.2 (N) 51 (N) 47.6 (N) 3.6 (N) 11.7 (N) 50 (N) 46.5 (N) 12.1 (N) 62 (N) 
6 2.7 (N) 14.1 (N) 54 (N) N/A 4.1 (N) 6.3 (N) 48 (N) 48.4 (N) 11.3 (N) 60 (N) 
7 3.8 (N) 29.1 (N) 51 (N) 43.7 (N) 3.0 (N) 7.4 (N) 58 (N) 40.7 (N) 22.2 (N) 59 (N) 
8 4.9 (N) 17.6 (N) 67 (N) 48.7 (N) 3.1 (N) 6.0 (N) 48 (N) 44.8 (N) 22.6 (N) 60 (N) 
9 3.8 (N) 24.5 (N) 53 (N) 48.1 (N) 4.2 (N) 17.0 (N) 50 (N) 45.9 (N) 27.9 (N) 61 (N) 
10 3.2 (N) 25.2 (N) 52 (N) 49.7 (N) 3.4 (N) 6.1 (N) 48 (N) 48.1 (N) 10.1 (N) 58 (N) 
11 4.4 (N) 23.7 (N) 53 (N) 51.7 (N) 3.9 (N) 6.5 (N) 51 (N) 48.4 (N) 6.3 (P) 52 (N) 
12 3.3 (N) 30.4 (N) 55 (N) 50.1 (N) 3.4 (N) 5.3 (N) 51 (N) 47.6 (N) 10.3 (N) 58 (N) 
13 3.2 (N) 25.2 (N) 55 (N) 51.1 (N) 3.8 (N) 12.7 (N) 51 (N) 48.6 (N) 6.9 (P) 59 (N) 
14 3.3 (N) 28.9 (N) 50 (N) 51.1 (N) 4.4 (N) 5.1 (N) 47 (N) 49.9 (N) 11.5 (N) 59 (N) 
15 3.6 (N) 7.1 (N) 44 (N) Absent (P) 3.8 (N) 4.9 (N) 41 (N) Absent (P) 5.0 (P) 58 (N) 
16 4.1 (N) 22.3 (N) 59 (N) 47,3 (N) 3.2 (N) 8.0 (N) 54 (N) 40.3 (N) 21.1 (N) 58 (N) 
17 4.0 (N) 12.3 (N) 51 (N) 49.4 (N) 4.9 (N) 4.8 (N) 46 (N) 51.4 (N) 13.7 (N) 48 (N) 
18 3.0 (N) 19.3 (N) 52 (N) 46.3 (N) 3.1 (N) 4.1 (N) 51 (N) 43.2 (N) 11.7 (N) 55 (N) 
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DML = distal motor latency; CMAP = compound muscle action potential; NCV = nerve conduction velocity; SNAP = sensory nerve action potential; N = normal; P 
= pathological 
19 5.0 (N) 13.1 (N) 54 (N) 54.7 (N) 4.4 (N) 4.7 (N) 49 (N) 49.8 (N) 10.0 (N) 48 (N) 
20 3.2 (N) 22.0 (N) 49 (N) 49.8 (N) 4.0 (N) 8.7 (N) 50 (N) 48.0 (N) 11.6 (N) 56 (N) 
21 3.5 (N) 33.6 (N) 53 (N) 47.7 (N) 3.5 (N) 5.5 (N) 51 (N) 45.7 (N) 15.6 (N) 55 (N) 
22 3.1 (N) 35.5 (N) 61 (N) 43.3 (N) 3.3 (N) 8.5 (N) 57 (N) 40.9 (N) 22.4 (N) 59 (N) 
23 4.6 (N) 33.9 (N) 49 (N) 44.7 (N) 3.6 (N) 6.1 (N) 48 (N) Absent (P) 11.7 (N) 49 (N) 
24 5.0 (N) 13.6 (N) 45 (N) 54.6 (N) 4.0 (N) 10.5 (N) 44 (N) 49.0 (N) 14.6 (N) 54 (N) 
25 3.3 (N) 23.5 (N) 53 (N) 48.0 (N) 4.3 (N) 5.4 (N) 49 (N) 48.0 (N) 14.8 (N) 55 (N) 
26 4.0 (N) 24.1 (N) 49 (N) 52.9 (N) 4.3 (N) 8.3 (N) 50 (N) 48.9 (N) 10.6 (N) 51 (N) 
27 3.9 (N) 16.1 (N) 53 (N) 52.8 (N) 4.2 (N) 5.0 (N) 45 (N) 53.2 (N) 12.3 (N) 61 (N) 
28 4.3 (N) 19.4 (N) 55 (N) 51.7 (N) 4.7 (N) 9.2 (N) 51 (N) 48.7 (N) 14.7 (N) 50 (N) 
29 3.2 (N) 19.4 (N) 51 (N) 48.4 (N) 3.9 (N) 10.0 (N) 49 (N) 45.1 (N) 12.6 (N) 57 (N) 
30 3.0 (N) 33.7 (N) 54 (N) 44.8 (N) 3.9 (N) 5.4 (N) 50 (N) 42.7 (N) 17.4 (N) 63 (N) 
31 3.1 (N) 28.2 (N) 51 (N) 49.0 (N) 4.1 (N) 11.4 (N) 48 (N) 42.9 (N) 13.0 (N) 59 (N) 
32 3.4 (N) 22.4 (N) 61 (N) 42.6 (N) 3.4 (N) 9.8 (N) 51 (N) 41.5 (N) 18.0 (N) 66 (N) 
33 3.4 (N) 30.7 (N) 52 (N) 49.2 (N) 3.9 (N) 6.5 (N) 49 (N) 46.2 (N) 13.6 (N) 55 (N) 
34 3.2 (N) 28.0 (N) 50 (N) 43.0 (N) 4.1 (N) 8.0 (N) 57 (N) 44.0 (N) 15.1 (N) 66 (N) 
35 3.8 (N) 26.0 (N) 49 (N) 51.0 (N) 4.0 (N) 9.2 (N) 49 (N) 48.0 (N) 8.7 (P) 50 (N) 
36 2.9 (N) 24.7 (N) 53 (N) 53.0 (N) 4.4 (N) 8.4 (N) 54 (N) 48.0 (N) 18.5 (N) 46 (N) 
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